Kawasaki Disease and Coronary Complications
Research Guide

Kawasaki disease diagnosis requires fever lasting at least 5 days plus four of five principal features: bilateral nonexudative conjunctivitis, oral mucosal changes, peripheral extremity changes, polymorphous rash, and cervical lymphadenopathy. Newburger et al. (2004) in "Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease" note that incomplete cases with fewer features require supplementary lab and echocardiographic findings. Coronary artery involvement guides urgent evaluation.

Intravenous immunoglobulin reduces coronary artery aneurysm formation from ≈25% in untreated cases to 5% when given within 10 days of fever onset. McCrindle et al. (2017) in "Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association" recommend a single 2 g/kg dose plus aspirin. This therapy targets vasculitis and inflammation effectively.

Coronary artery aneurysms or ectasia develop in ∼25% of untreated Kawasaki disease patients, leading to acquired heart disease. Whittaker et al. (2020) in "Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2" observed coronary artery aneurysms in cases resembling Kawasaki disease. Long-term management involves echocardiographic surveillance per AHA guidelines.

SARS-CoV-2 infection associates with multisystem inflammatory syndrome in children featuring Kawasaki-like symptoms including coronary abnormalities. Verdoni et al. (2020) in "An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study" described 30 cases with shock and cardiac involvement post-SARS-CoV-2. Feldstein et al. (2020) in "Multisystem Inflammatory Syndrome in U.S. Children and Adolescents" reported serious illness in previously healthy children.

AHA scientific statements outline diagnosis, acute treatment with IVIG and aspirin, and long-term coronary monitoring based on risk levels. McCrindle et al. (2017) updated prior guidelines from Newburger et al. (2004), emphasizing early intervention to prevent aneurysms. Risk scores predict IVIG resistance for intensified therapy.